|
Jul 27
|
Pharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutions
|
|
Jul 24
|
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Jul 23
|
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jul 22
|
Pharvaris Announces Proposed Public Offering of Ordinary Shares
|
|
Jun 27
|
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
|
|
May 13
|
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
|
|
May 12
|
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
|
|
Apr 7
|
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Apr 1
|
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
|